{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:28:17Z","timestamp":1778581697658,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1007\/s11894-007-0069-1","type":"journal-article","created":{"date-parts":[[2007,12,6]],"date-time":"2007-12-06T16:03:30Z","timestamp":1196957010000},"page":"521-527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Positioning biologic therapy for Crohn\u2019s disease and ulcerative colitis"],"prefix":"10.1007","volume":"9","author":[{"given":"Fernando S.","family":"Velayos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,12,6]]},"reference":[{"key":"69_CR1","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/gut.49.6.777","volume":"49","author":"E. Louis","year":"2001","unstructured":"Louis E, Collard A, Oger AF, et al.: Behaviour of Crohn\u2019s disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001, 49:777\u2013782.","journal-title":"Gut"},{"key":"69_CR2","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/0016-5085(93)91068-S","volume":"105","author":"P. Munkholm","year":"1993","unstructured":"Munkholm P, Langholz E, Davidsen M, Binder V: Intestinal cancer risk and mortality in patients with Crohn\u2019s disease. Gastroenterology 1993, 105:1716\u20131723.","journal-title":"Gastroenterology"},{"key":"69_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/gast.2001.26279","volume":"121","author":"W.A. Faubion Jr","year":"2001","unstructured":"Faubion WA, Jr, Loftus EV, Jr, Harmsen WS, et al.: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255\u2013260.","journal-title":"Gastroenterology"},{"key":"69_CR4","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/0016-5085(90)90613-6","volume":"99","author":"P. Rutgeerts","year":"1990","unstructured":"Rutgeerts P, Geboes K, Vantrappen G, et al.: Predictability of the postoperative course of Crohn\u2019s disease. Gastroenterology 1990, 99:956\u2013963.","journal-title":"Gastroenterology"},{"key":"69_CR5","unstructured":"Sutherland L, Roth D, Beck P, et al.: Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. Cochrane Database Syst Rev 2000, (2):CD000543."},{"key":"69_CR6","doi-asserted-by":"crossref","unstructured":"Akobeng AK, Gardener E: Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn\u2019s disease. Cochrane Database Syst Rev 2005, (1):CD003715.","DOI":"10.1002\/14651858.CD003715.pub2"},{"key":"69_CR7","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJM199409293311303","volume":"331","author":"G.R. Greenberg","year":"1994","unstructured":"Greenberg GR, Feagan BG, Martin F, et al.: Oral budesonide for active Crohn\u2019s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994, 331:836\u2013841.","journal-title":"N Engl J Med"},{"key":"69_CR8","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1111\/j.1572-0241.2005.41992.x","volume":"100","author":"W.J. Sandborn","year":"2005","unstructured":"Sandborn WJ, Lofberg R, Feagan BG, et al.: Budesonide for maintenance of remission in patients with Crohn\u2019s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005, 100:1780\u20131787.","journal-title":"Am J Gastroenterol"},{"key":"69_CR9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","volume":"77","author":"R.W. Summers","year":"1979","unstructured":"Summers RW, Switz DM, Sessions JT, Jr, et al.: National Cooperative Crohn\u2019s Disease Study: results of drug treatment. Gastroenterology 1979, 77:847\u2013869.","journal-title":"Gastroenterology"},{"key":"69_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S0140-6736(65)90973-6","volume":"1","author":"J.E. Lennard-Jones","year":"1965","unstructured":"Lennard-Jones JE, Misiewicz JJ, Connell AM, et al.: Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet 1965, 1:188\u2013189.","journal-title":"Lancet"},{"key":"69_CR11","unstructured":"Sandborn W, Sutherland L, Pearson D, et al.: Azathioprine or 6-mercaptopurine for inducing remission of Crohn\u2019s disease. Cochrane Database Syst Rev 2000, (2):CD000545."},{"key":"69_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199502023320503","volume":"332","author":"B.G. Feagan","year":"1995","unstructured":"Feagan BG, Rochon J, Fedorak RN, et al.: Methotrexate for the treatment of Crohn\u2019s disease. The North American Crohn\u2019s Study Group Investigators. N Engl J Med 1995, 332:292\u2013297.","journal-title":"N Engl J Med"},{"key":"69_CR13","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1136\/gut.37.5.674","volume":"37","author":"S. Candy","year":"1995","unstructured":"Candy S, Wright J, Gerber M, et al.: A controlled double blind study of azathioprine in the management of Crohn\u2019s disease. Gut 1995, 37:674\u2013678.","journal-title":"Gut"},{"key":"69_CR14","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","volume":"342","author":"B.G. Feagan","year":"2000","unstructured":"Feagan BG, Fedorak RN, Irvine EJ, et al.: A comparison of methotrexate with placebo for the maintenance of remission in Crohn\u2019s disease. The North American Crohn\u2019s Study Group Investigators. N Engl J Med 2000, 342:1627\u20131632.","journal-title":"N Engl J Med"},{"key":"69_CR15","doi-asserted-by":"crossref","unstructured":"Timmer A, McDonald JW, Macdonald JK: Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007, (1):CD000478.","DOI":"10.1002\/14651858.CD000478.pub2"},{"key":"69_CR16","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"S.B. Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet 2002, 359:1541\u20131549.","journal-title":"Lancet"},{"key":"69_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"J.F. Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, et al.: Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology 2007, 132:52\u201365.","journal-title":"Gastroenterology"},{"key":"69_CR18","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa043335","volume":"353","author":"W.J. Sandborn","year":"2005","unstructured":"Sandborn WJ, Colombel JF, Enns R, et al.: Natalizumab induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med 2005, 353:1912\u20131925.","journal-title":"N Engl J Med"},{"key":"69_CR19","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.14309\/00000434-200609001-01109","volume":"101","author":"W. Sandborn","year":"2006","unstructured":"Sandborn W, Colombel JF, Panes J, et al.: Higher remission and maintenance of response rates with subcutaneously monthly certolizumab pegol in patients with recent onset Crohn\u2019s disease: data from PRECiSE2. Am J Gastroenterol 2006, 101:S434\u2013S435.","journal-title":"Am J Gastroenterol"},{"key":"69_CR20","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Feagan BG, Stoinov S, et al.: Certolizumab pegol for the treatment of Crohn\u2019s disease. N Engl J Med 2007, [In press].","DOI":"10.1056\/NEJMoa067594"},{"key":"69_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa062897","volume":"357","author":"S. Schreiber","year":"2007","unstructured":"Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al.: Maintenance therapy with certolizumab pegol for Crohn\u2019s disease. N Engl J Med 2007, 357:239\u2013250.","journal-title":"N Engl J Med"},{"key":"69_CR22","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P. Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462\u20132476.","journal-title":"N Engl J Med"},{"key":"69_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1365-2036.2007.03361.x","volume":"26","author":"W.J. Sandborn","year":"2007","unstructured":"Sandborn WJ, Kamm MA, Lichtenstein GR, et al.: MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007, 26:205\u2013215.","journal-title":"Aliment Pharmacol Ther"},{"key":"69_CR24","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0016-5085(99)70125-3","volume":"116","author":"G. Hellers","year":"1999","unstructured":"Hellers G, Cortot A, Jewell D, et al.: Oral budesonide for prevention of postsurgical recurrence in Crohn\u2019s disease. The IOIBD Budesonide Study Group. Gastroenterology 1999, 116:294\u2013300.","journal-title":"Gastroenterology"},{"key":"69_CR25","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0016-5085(90)90002-I","volume":"98","author":"R. Modigliani","year":"1990","unstructured":"Modigliani R, Mary JY, Simon JF, et al.: Clinical, biological, and endoscopic picture of attacks of Crohn\u2019s disease. Evolution on prednisolone Groupe d\u2019Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990, 98:811\u2013818.","journal-title":"Gastroenterology"},{"key":"69_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0016-5107(99)80017-0","volume":"50","author":"G. D\u2019Haens","year":"1999","unstructured":"D\u2019Haens G, Geboes K, Rutgeerts P: Endoscopic and histologic healing of Crohn\u2019s (ileo-)colitis with azathioprine. Gastrointest Endosc 1999, 50:667\u2013671.","journal-title":"Gastrointest Endosc"},{"issue":"Suppl","key":"69_CR27","first-page":"A49","volume":"128","author":"R. Panaccione","year":"2005","unstructured":"Panaccione R: The use of methotrexate is associated with mucosal healing in Crohn\u2019s disease. Gastroenterology 2005, 128(Suppl):A49.","journal-title":"Gastroenterology"},{"key":"69_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/gut.2005.068809","volume":"55","author":"S. Ardizzone","year":"2006","unstructured":"Ardizzone S, Maconi G, Russo A, et al.: Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55:47\u201353.","journal-title":"Gut"},{"key":"69_CR29","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJM198005013021801","volume":"302","author":"D.H. Present","year":"1980","unstructured":"Present DH, Korelitz BI, Wisch N, et al.: Treatment of Crohn\u2019s disease with 6-mercaptopurine: a long-term, randomized, double-blind study. N Engl J Med 1980, 302:981\u2013987.","journal-title":"N Engl J Med"},{"key":"69_CR30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1053\/j.gastro.2004.06.002","volume":"127","author":"S.B. Hanauer","year":"2004","unstructured":"Hanauer SB, Korelitz BI, Rutgeerts P, et al.: Postoperative maintenance of Crohn\u2019s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004, 127:723\u2013729.","journal-title":"Gastroenterology"},{"key":"69_CR31","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","volume":"116","author":"G. D\u2019Haens","year":"1999","unstructured":"D\u2019Haens G, van Deventer S, Van Hogzand R, et al.: Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn\u2019s disease: a European multicenter trial. Gastroenterology 1999, 116:1029\u20131034.","journal-title":"Gastroenterology"},{"key":"69_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.gie.2005.08.011","volume":"63","author":"P. Rutgeerts","year":"2006","unstructured":"Rutgeerts P, Diamond RH, Bala M, et al.: Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn\u2019s disease. Gastrointest Endosc 2006, 63:433\u2013442, quiz 64.","journal-title":"Gastrointest Endosc"},{"key":"69_CR33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1136\/gut.2004.045294","volume":"54","author":"J. Cosnes","year":"2005","unstructured":"Cosnes J, Nion-Larmurier I, Beaugerie L, et al.: Impact of the increasing use of immunosuppressants in Crohn\u2019s disease on the need for intestinal surgery. Gut 2005, 54:237\u2013241.","journal-title":"Gut"},{"key":"69_CR34","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1136\/ard.47.8.648","volume":"47","author":"T.T. Mottonen","year":"1988","unstructured":"Mottonen TT: Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 1988, 47:648\u2013653.","journal-title":"Ann Rheum Dis"},{"key":"69_CR35","first-page":"2208","volume":"22","author":"C. Egsmose","year":"1995","unstructured":"Egsmose C, Lund B, Borg G, et al.: Patients with rheumatoid arthritis benefit from early second line therapy: 5 year follow-up of a prospective double blind placebo controlled study. J Rheumatol 1995, 22:2208\u20132213.","journal-title":"J Rheumatol"},{"key":"69_CR36","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","volume":"146","author":"Y.P. Goekoop-Ruiterman","year":"2007","unstructured":"Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al.: Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007, 146:406\u2013415.","journal-title":"Ann Intern Med"},{"key":"69_CR37","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1046\/j.1365-2036.2003.01672.x","volume":"18","author":"P. Lionetti","year":"2003","unstructured":"Lionetti P, Bronzini F, Salvestrini C, et al.: Response to infliximab is related to disease duration in paediatric Crohn\u2019s disease. Aliment Pharmacol Ther 2003, 18:425\u2013431.","journal-title":"Aliment Pharmacol Ther"},{"key":"69_CR38","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","volume":"132","author":"J.S. Hyams","year":"2007","unstructured":"Hyams JS, Crandall W, Kugathasan S, et al.: Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children. Gastroenterology 2007, 132:863\u2013873.","journal-title":"Gastroenterology"},{"key":"69_CR39","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1053\/gast.2000.18144","volume":"119","author":"J. Markowitz","year":"2000","unstructured":"Markowitz J, Grancher K, Kohn N, et al.: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn\u2019s disease. Gastroenterology 2000, 119:895\u2013902.","journal-title":"Gastroenterology"},{"key":"69_CR40","first-page":"A147","volume":"132","author":"S. Schreiber","year":"2007","unstructured":"Schreiber S, Reinisch W, Colombel JF, et al.: Early Crohn\u2019s disease shows high levels of remission to therapy with adalimumab. Sub-analysis of CHARM. Gastroenterology 2007, 132:A147.","journal-title":"Gastroenterology"},{"key":"69_CR41","first-page":"A509","volume":"132","author":"S. Schreiber","year":"2007","unstructured":"Schreiber S, Targan S: Efficacy of natalizumab in Crohn\u2019s patients with disease duration less than 3 years. Gastroenterology 2007, 132:A509.","journal-title":"Gastroenterology"},{"key":"69_CR42","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","volume":"130","author":"M. Lemann","year":"2006","unstructured":"Lemann M, Mary JY, Duclos B, et al.: Infliximab plus azathioprine for steroid-dependent Crohn\u2019s disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130:1054\u20131061.","journal-title":"Gastroenterology"},{"key":"69_CR43","first-page":"A108","volume":"130","author":"D.W. Hommes","year":"2006","unstructured":"Hommes DW, Baert F, van Assche G, et al.: A randomized controlled trial evaluating the ideal medical management for Crohn\u2019s disease (CD): top-down versus step-up strategies. Gastroenterology 2006, 130:A108\u2013A109.","journal-title":"Gastroenterology"},{"key":"69_CR44","first-page":"A110","volume":"130","author":"G. D\u2019Haens","year":"2006","unstructured":"D\u2019Haens G, Hommes DW, Baert F, et al.: A combined regimen of infliximab and azathioprine induces better endoscopic healing than the classic step-up therapy in newly diagnosed Crohn\u2019s. Gastroenterology 2006, 130:A110.","journal-title":"Gastroenterology"},{"key":"69_CR45","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/01.md.0000180044.19285.9a","volume":"84","author":"N.F. Crum","year":"2005","unstructured":"Crum NF, Lederman ER, Wallace MR: Infections associated with tumor necrosis factor-alpha antagonists. Medicine 2005, 84:291\u2013302.","journal-title":"Medicine"},{"key":"69_CR46","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cgh.2007.02.016","volume":"5","author":"R.A. Hansen","year":"2007","unstructured":"Hansen RA, Gartlehner G, Powell GE, Sandler RS: Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol 2007, 5:729\u2013735e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"69_CR47","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","volume":"44","author":"A.C. Mackey","year":"2007","unstructured":"Mackey AC, Green L, Liang LC, et al.: Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. Journal Pediatr Gastroenterol Nutr 2007, 44:265\u2013267.","journal-title":"Journal Pediatr Gastroenterol Nutr"},{"key":"69_CR48","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa054693","volume":"354","author":"T.A. Yousry","year":"2006","unstructured":"Yousry TA, Major EO, Ryschkewitsch C, et al.: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006, 354:924\u2013933.","journal-title":"N Engl J Med"},{"key":"69_CR49","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","volume":"4","author":"G.R. Lichtenstein","year":"2006","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, et al.: Serious infections and mortality in association with therapies for Crohn\u2019s disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621\u2013630.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"69_CR50","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1053\/j.gastro.2005.12.019","volume":"130","author":"L. Beaugerie","year":"2006","unstructured":"Beaugerie L, Seksik P, Nion-Larmurier I, et al.: Predictors of Crohn\u2019s disease. Gastroenterology 2006, 130:650\u2013656.","journal-title":"Gastroenterology"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-007-0069-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-007-0069-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-007-0069-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-007-0069-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:18:08Z","timestamp":1652660288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-007-0069-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["69"],"URL":"https:\/\/doi.org\/10.1007\/s11894-007-0069-1","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"6 December 2007","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}